Surveillance for Cutaneous Malignant Neoplasms Recommended in Post-BMT Patients – Oncology Nurse Advisor
Researchers explored the risks for basal cell carcinoma, squamous cell carcinoma, and melanoma in patients who underwent BMT.
Related Articles
China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.
Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.
Guideline Task Force Nomination Application – American Society for Radiation Oncology (ASTRO)
ASTRO welcomes nominations for participation in upcoming practice guidelines. Please complete this form for consideration.
Novel HER2 TKI Shows Preliminary Activity in Breast Cancer Brain Metastases
Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.
Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel
Panelists discuss how the major unmet needs in treating synovial sarcoma include developing targeted therapies that effectively address the SS18::SSX fusion oncogene, improving early detection…
Addition of an immune checkpoint inhibitor reduces the risk of disease progression for select patients with anal cancer
Click on the article title to read more.
Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD
Chandler Park, MD and Joshua Brody, MD discusses treatment challenges posed by the diverse spectrum of lymphomas, ranging from indolent subtypes, to aggressive diseases like…
CDC awards $2.3M research grant for young patients with breast cancer
The CDC has awarded Weill Cornell Medicine a 5-year, $2.3 million grant to advance equitable access to care for young patients with breast cancer. The…
First-Line Belzutifan/Cabozantinib Delivers Responses and Manageable Toxicities in ccRCC
Frontline belzutifan plus cabozantinib elicited durable responses and was tolerable in patients with treatment-naive advanced ccRCC.